Gammapatías monoclonales

El objetivo de la presente guía es confeccionar pautas de diagnóstico y tratamiento de los desórdenes a células plasmáticas, teniendo en cuenta las recomendaciones de expertos así como las publicaciones internacionales relacionadas al tema, la disponibilidad de recursos locales y la experiencia de los especialistas convocados, La misma contempla: establecer pautas diagnósticas, clasificar y establecer factores pronósticos, unificar recomendaciones terapéuticas y contribuir a la toma de decisiones.Fil: Arriola, Juan. No especifíca;Fil: Duarte, Patricio. No especifíca;Fil: Fantl, Dorotea. No especifíca;Fil: Garate, Gonzalo. No especifíca;Fil: Lopresti, Sergio. No especifíca;Fil: Ochoa, Paola. No especifíca;Fil: Quiroga, Luis. No especifíca;Fil: Remaggi, Guillermina. No especifíca;Fil: Schutz, Natalia. No especifíca;Fil: Seehaus, Cristian. No especifíca;Fil: Slavutsky, Irma Rosa. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Zabaljauregui, Soledad. No especifíca

PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial

The role of Ann Arbor staging in determining treatment intensity after achieving a negative positron emission tomography (PET) has not been established in classical Hodgkin lymphoma (cHL). Patients with stage I–IV cHL, received three cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and an interim PET scan (PET3). PET3-negative patients received no further therapy. PET3-positive patients received three additional cycles of ABVD plus involved-field radiation therapy or salvage chemotherapy, if refractory to ABVD, and were re-evaluated by PET scan (PET6). Study endpoints were 3-year progression-free survival (PFS) and overall survival (OS) rates. Two hundred and thirty-nine patients with early-stage and 138 with advanced-stage were evaluable. Overall, 260 patients (70%) were PET3-negative and had higher 3-year PFS (90% vs. 65%; P < 0 0001) and OS (98% vs. 92%; P = 0 007) rates than PET3-positive patients. All PET3-negative patients, regardless of disease stage at diagnosis, achieved similarly good PFS (90–91%; P = 0 76) and OS (97–99%). The only independent prognostic factor for PFS was PET3-negativity (Hazard ratio 3 8; 95% confidence interval 2 4–6 3; P < 0 0001). This study suggests that cHL patients who achieve a negative PET3 following ABVD have an excellent outcome, regardless of stage at diagnosis. An appropriately powered, phase III trial will be necessary to confirm these findings.Fil: Pavlovsky, Astrid. Fundación Para Combatir la Leucemia; Argentina. Centro de Hematología Pavlovsky; ArgentinaFil: Fernández, Isolda. Fundación Para Combatir la Leucemia; Argentina. Centro de Hematología Pavlovsky; ArgentinaFil: Kurgansky, Nicolas. Doctus; ArgentinaFil: Prates, Virginia. Hospital Italiano de La Plata; ArgentinaFil: Zoppegno, Lucia. Hospital General San Martín; ArgentinaFil: Negri, Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Instituto Privado de Hematología y Hemoterapia; ArgentinaFil: Milone, Gustavo. Fundación Para Combatir la Leucemia; ArgentinaFil: Cerutti, Ider. Idhea Clinica Hematologica Dr Cerutti Ider; ArgentinaFil: Zabaljauregui, Soledad. Academia Nacional de Medicina de Buenos Aires; ArgentinaFil: Mariano, Romina. Provincia de Entre Rios. Hospital San Martin; ArgentinaFil: Grecco, Horacio F.. Sanatorio Dr. Julio Méndez; ArgentinaFil: Basquiera, Ana Lisa. Hospital Privado Universitario de Cordoba.; ArgentinaFil: Saba, Silvia. Hospital Rodolfo Rossi; ArgentinaFil: Rudoy, Silvia. Clínica Modelo de Morón; ArgentinaFil: Sackmann, Federico. Fundación Para Combatir la Leucemia; ArgentinaFil: Castano, Vanesa. Idhea Clinica Hematologica Dr Cerutti Ider; ArgentinaFil: Remaggi, Guillermina. Fundación Para Combatir la Leucemia; ArgentinaFil: Cabrejo, María del Rosario. Sanatorio Dr. Julio Méndez; ArgentinaFil: Roveri, Eriberto. Idhea Clinica Hematologica Dr Cerutti Ider; ArgentinaFil: Casale, María Florencia. Instituto Privado de Hematología y Hemoterapia; Argentina. Hospital General Centeno; ArgentinaFil: Cabane, Vanina. Clínica Dr. Roberto Raña; ArgentinaFil: Taus, Rossana. Hospital Rodolfo Rossi; ArgentinaFil: Venturini, Claudia. Instituto Privado de Hematología y Hemoterapia; ArgentinaFil: Sakamoto, Francisco. Instituto Privado de Hematología y Hemoterapia; ArgentinaFil: Varela, Ana I.. Sanatorio Las Lomas Sociedad Anonima.; ArgentinaFil: Riddick, Maximiliano Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Departamento de Matemáticas; ArgentinaFil: Pavlovsky, Santiago. Fundación Para Combatir la Leucemia; Argentin

Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study

The aim of this study was to describe clinical and survival characteristics of transplant-eligible multiple myeloma (MM) patients in Latin America (LA), with a special focus on differences between public and private healthcare facilities. We included 1293 patients diagnosed between 2010 and 2018. A great disparity in outcomes and survival between both groups was observed. Late diagnosis and low access to adequate frontline therapy and ASCT in public institutions probably explain these differences. Patients treated with novel drug induction protocols, followed by autologous stem cell transplantation (ASCT) and maintenance, have similar overall survival compared to that published internationally